Trimetazidine improves myocardial energy efficiency in MYH7 mutation carriers
ID
Bron
Verkorte titel
Aandoening
Hypertrophic Cardiomyopathy
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
Myocardial energy efficiency, as measured by PET/CT and CMR
Achtergrond van het onderzoek
Aims: Previous studies have shown that HCM mutation carriers have a decreased myocardial energy efficiency, which is thought to play a key role in the pathomechanism of HCM. The ENERGY trial aims to determine whether metabolic drugs correct decreased myocardial energy efficiency in HCM mutation carriers at an early disease stage.
Methods: 40 genotype-positive, phenotype-negative MYH7 mutation carriers will be treated for two months with trimetazidine or placebo in a double-blind randomized study design. Directly before and after treatment, study subjects will undergo an [11C]-acetate PET/CT and CMR scan to measure myocardial energy efficiency. Myocardial efficiency will be calculated as the amount of oxygen used by the heart to perform work.
Conclusion: The ENERGY trial will be the first proof-of-concept to determine whether metabolic drugs are a potential preventive therapy for HCM. Given that trimetazidine is already used in clinical practice, there is large potential to swiftly implement this drug in HCM therapy.
Doel van het onderzoek
Trimetazidine improves myocardial energy efficiency in MYH7 mutation carriers
Onderzoeksopzet
Last patient last visit
Onderzoeksproduct en/of interventie
Trimetazidine 20mg 3dd
Publiek
Beau van Driel
+31620673492
b.vandriel@vumc.nl
Wetenschappelijk
Beau van Driel
+31620673492
b.vandriel@vumc.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
18-65 years old
Class 5 MYH7 mutation identified by pre-symptomatic genetic screening
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
Cardiovascular disease
- Hypertrophic Cardiomyopathy (Maximal Wall Thickness >15mm)
- Wall motion disorders
Diabetes mellitus
Any absolute or relative contra-indication for MRI (i.e. metallic implants and claustrophobia)
Inability to give informed consent.
Severely impaired renal function with a GFR < 30 ml/min
Parkinson disease and related symptoms
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL7492 |
| Ander register | METC VUmc : 2018.344 |